VIVUS (VVUS) Qsymia Prescriptions Fall for Second Week; Promotion Still Ongoing
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
Prescriptions for VIVUS (Nasdaq: VVUS) Qsymia were light for a second-straight week, pressuring shares Monday.
Data from Symphony Health shows a 1 percent drop in Qsymia prescriptions for the week ended March 29th:
Bloomberg Industries notes that low-dose is down 14.4 percent from a peak hit on February 8th. VIVUS is currently promoting an introductory Qsymia dose for no-cost, while VIVUS brings in no revenue on the promotion.
Shares of VIVUS are down 1.3 percent.
Data from Symphony Health shows a 1 percent drop in Qsymia prescriptions for the week ended March 29th:
- Low-dose Qsymia TRx were at 1,540, from 1,557 the prior period;
- Medium-dose came in at 2,076, from a prior read of 2,200 prescriptions; and
- High-dose TRx came in at 116, from 90 the previous week.
Bloomberg Industries notes that low-dose is down 14.4 percent from a peak hit on February 8th. VIVUS is currently promoting an introductory Qsymia dose for no-cost, while VIVUS brings in no revenue on the promotion.
Shares of VIVUS are down 1.3 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) CEO to testify at May 1 House Panel hearing
- US stocks saw largest 2-week outflow since December 2022 - BofA
- Handful of Companies Said to Receive Comments from Specialty Firm
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
